School of Chemistry, University of Leicester, Leicester LE1 7RH, UK.
Inorganic Chemistry I, Ruhr-Universität Bochum, Universitätsstr. 150, 44801 Bochum, Germany.
Molecules. 2024 Jun 8;29(12):2743. doi: 10.3390/molecules29122743.
Cobalt(III) compounds with tetradentate ligands have been widely employed to deliver cytotoxic and imaging agents into cells. A large body of work has focused on using cobalt(III)-cyclam scaffolds for this purpose. Here, we investigate the cytotoxic properties of cobalt(III) complexes containing 14-membered macrocycles related to cyclam. A breast cancer stem cell (CSC) in vitro model was used to gauge efficacy. Specifically, [Co(1,4,7,11-tetraazacyclotetradecane)Cl] () and [Co(1-oxa-4,8,12-triazacyclotetradecane)Cl] () were synthesised and characterised, and their breast CSC activity was determined. The cobalt(III) complexes and displayed micromolar potency towards bulk breast cancer cells and breast CSCs grown in monolayers. Notably, and displayed selective potency towards breast CSCs over bulk breast cancer cells (up to 4.5-fold), which was similar to salinomycin (an established breast CSC-selective agent). The cobalt(III) complexes and were also able to inhibit mammosphere formation at low micromolar doses (with respect to size and number). The mammopshere inhibitory effect of was similar to that of salinomycin. Our studies show that cobalt(III) complexes with 1,4,7,11-tetraazacyclotetradecane and 1-oxa-4,8,12-triazacyclotetradecane macrocycles could be useful starting points for the development of new cobalt-based delivery systems that can transport cytotoxic and imaging agents into breast CSCs.
钴(III)配合物与四齿配体广泛用于将细胞毒性和成像剂递送至细胞内。大量工作集中在使用钴(III)-环戊二烯支架来实现这一目的。在这里,我们研究了含有与环戊二烯相关的 14 元大环的钴(III)配合物的细胞毒性特性。体外乳腺癌干细胞 (CSC) 模型用于评估功效。具体而言,合成并表征了 Co(1,4,7,11-四氮杂环十四烷)Cl 和 Co(1-氧杂-4,8,12-三氮杂环十四烷)Cl,并测定了它们对乳腺癌 CSC 的活性。钴(III)配合物 和 对单层培养的乳腺癌细胞和乳腺癌 CSCs 具有微摩尔效力。值得注意的是, 和 对乳腺癌 CSCs 的选择性效力优于乳腺癌细胞 (高达 4.5 倍),与杀稻瘟菌素 (一种已建立的乳腺癌 CSC 选择性试剂) 相似。钴(III)配合物 和 还能够以低微摩尔剂量抑制类乳腺球体的形成 (相对于大小和数量)。 的类乳腺球体抑制作用与杀稻瘟菌素相似。我们的研究表明,具有 1,4,7,11-四氮杂环十四烷和 1-氧杂-4,8,12-三氮杂环十四烷大环的钴(III)配合物可能是开发新的钴基递药系统的有用起点,该系统可以将细胞毒性和成像剂递送至乳腺癌 CSCs。